On this page
Key takeaways
• Sasaki 2020 is the load-bearing paper — topical fisetin promoted hair growth in mice by activating TERT (telomerase reverse transcriptase) expression in follicular keratinocytes (1).
• The mouse work used topical application, not oral capsules. Translating the finding to human oral fisetin supplementation is speculative.
• Grey hair reversal reports are anecdotal and forum-based — no controlled human trial has demonstrated that fisetin (oral or topical) reverses grey hair.
• Grey hair biology involves melanocyte stem cell depletion in the follicular niche (3,8). Fisetin’s specific effect on this population has not been characterised.
• Minoxidil remains the evidence-based topical hair growth treatment with dozens of positive human RCTs (2). Fisetin is not an established substitute.
• Combined hair loss protocols using fisetin, quercetin, and other flavonoids have accumulated among longevity practitioners but lack clinical validation.
Quick answer
Fisetin has one meaningful hair-growth paper — Sasaki 2020, which reported that topical fisetin at 1% w/v in ethanol activated TERT expression in follicular keratinocytes and promoted hair growth in mice over 12 days (1). The mechanism is mechanistically interesting because telomerase activity supports the self-renewal capacity of follicular stem cells. But the paper used topical application in mice, and no human clinical trial has tested either oral or topical fisetin for hair outcomes. Grey hair reversal reports are anecdotal, mostly from longevity forums and social media, and have no controlled trial support. Established evidence-based hair treatments (minoxidil, finasteride) remain the appropriate first-line options for hair loss. Fisetin’s hair story is preclinical, promising, and unfinished. For the full clinical context, see our complete clinician’s guide.
The Sasaki 2020 paper — the TERT signal
Sasaki and colleagues (Front Cell Dev Biol, 2020) is the load-bearing paper for the fisetin hair story (1). The design combined a screening component with an in vivo test.
Screen. The authors screened food compounds for the ability to activate the TERT promoter in keratinocytes. Telomerase reverse transcriptase (TERT) is the catalytic component of the telomerase enzyme that maintains telomere length. Follicular stem cells that maintain robust TERT expression retain their self-renewal capacity; TERT decline is one of several drivers of follicular exhaustion in ageing hair loss. Fisetin was identified in this screen as a food-derived TERT promoter activator.
In vivo test. Topical fisetin at 1% w/v in 50% ethanol was applied to dorsal skin of C3H mice in the resting (telogen) phase of the hair cycle over 12 days. Fisetin-treated mice showed accelerated hair regrowth compared to vehicle-treated controls. Histology confirmed increased follicular activity and TERT expression.
A follow-up mechanism paper demonstrated that fisetin-treated keratinocytes released exosomes that themselves promoted hair growth in a paracrine manner — suggesting the mechanism involves both direct follicular effect and indirect signalling to surrounding tissue.
This is mechanistically interesting preclinical work. It is not evidence that oral fisetin capsules promote hair growth in humans.
The translation problem — topical mouse vs oral human
Two translational gaps sit between the Sasaki 2020 finding and consumer claims about fisetin capsules for hair loss.
Topical vs oral
The Sasaki experiment applied fisetin directly to skin at 1% w/v. This delivers pharmacologically meaningful concentrations to follicular tissue. Oral fisetin capsules, by contrast, produce plasma concentrations well below the range at which fisetin activates TERT in cell culture (6). The fraction of that plasma load reaching hair follicle stem cells is smaller still. For an oral capsule to reproduce the topical mouse result, plasma fisetin would need to distribute preferentially to follicular tissue — which has not been demonstrated. See our dedicated bioavailability article for the pharmacokinetic detail.
Mouse vs human
Mouse hair biology and human hair biology overlap substantially but not entirely. Mouse hair grows in synchronised follicular cycles that respond dramatically to topical treatments — including many that do not translate to human clinical benefit. Human hair grows in mosaic follicular cycles with much lower synchronisation. The specific responsiveness of human follicles to topical fisetin has not been tested in a controlled trial.
The grey hair question — different biology entirely
Grey hair is not simply the absence of hair growth — it is the specific loss of pigmentation caused by melanocyte stem cell dysfunction in the follicular bulge. This is a biologically distinct process from hair thinning or hair loss.
Nishimura and colleagues (Science, 2005) established that grey hair arises from incomplete maintenance of melanocyte stem cells in the follicular niche (3). As melanocyte stem cells are lost, newly generated hairs lack pigmentation. Sun and colleagues (Nature, 2023) extended this by showing that a polycomb repressive complex is required to maintain the pigmented state of hair follicle stem cells (8).
The Sasaki paper does not test melanocyte biology — it tests keratinocyte follicular activity and TERT expression. Whether fisetin has any specific effect on melanocyte stem cells has not been characterised. The extrapolation from "fisetin promotes hair growth in mice" to "fisetin reverses grey hair in humans" involves two mechanistic leaps that have not been experimentally validated: from keratinocyte TERT activation to melanocyte maintenance, and from mouse follicle biology to human melanogenesis. Both leaps are speculative.
The Rosenberg 2021 eLife paper offered a different insight relevant to grey hair reversal claims (7). Individual human hair strands can show reversal of greying over their length, correlating with reductions in life stress. This demonstrates that human grey hair is not always permanent — but the driver appears to be stress-related melanocyte reactivation, not any specific supplement intervention. Fisetin’s role in this process is untested.
The reddit / longevity forum culture
A distinctive feature of the fisetin-and-hair conversation is the volume of anecdotal reports from longevity supplement communities. Reports typically describe grey hair darkening, hair line filling in, or overall hair thickening after several months of continuous fisetin supplementation, often combined with high-dose quercetin, resveratrol, or other flavonoids. Photos are shared, before-and-after comparisons circulate, and the general vibe suggests fisetin is producing meaningful cosmetic hair effects.
These reports are difficult to evaluate. Confounders include self-selection (people who feel fisetin helped are more likely to post than people who noticed nothing), general regression to the mean in hair pattern (hair goes through natural cycles), concurrent lifestyle changes (stress reduction, dietary improvement, sleep changes), and the well-known responsiveness of hair perception to belief and attention. None of this rules out that fisetin has a real hair effect — but it means the community reports do not constitute clinical evidence. A single small controlled trial would be more informative than a hundred forum photos.
The evidence-based hair treatment landscape
For readers with actual hair loss (androgenic alopecia, telogen effluvium, alopecia areata), the appropriate first-line interventions remain evidence-based dermatological therapy.
• Topical minoxidil (2% or 5%) has dozens of positive RCTs and is the standard-of-care first-line topical hair growth therapy (2).
• Oral finasteride for men with androgenic alopecia is well-established. Oral minoxidil at low doses (0.25–1 mg daily) has emerging RCT support.
• PRP (platelet-rich plasma) injections have moderate RCT evidence for androgenic alopecia.
• Referral to a dermatologist is appropriate for any patterned or progressive hair loss.
Fisetin, in either oral or topical form, is not a replacement for these established therapies. It may reasonably be considered as an adjunct to established treatment for readers who want to explore the senolytic hypothesis or the TERT-activation mechanism, but it should not substitute for evidence-based hair loss therapy.
Practical guidance
If you want to explore fisetin for hair specifically:
• Topical is more mechanistically direct than oral for hair-follicle delivery. Commercial fisetin serums exist but vary in concentration and quality. A DIY approach dissolving fisetin powder at ~1% in a carrier oil is possible but stability and skin penetration are unpredictable.
• Continue any established hair loss treatment. Fisetin adds to — does not replace — minoxidil, finasteride, or other evidence-based therapy.
• Set realistic expectations. If fisetin has a real human hair effect, it will be modest and slow — visible only over months, not weeks. Any dramatic rapid change is more likely explained by other factors.
• Do not expect grey hair reversal. No controlled evidence supports this claim. Melanocyte biology is not addressed by any of the fisetin preclinical work.
What we still don't know
• Whether topical fisetin produces any hair growth benefit in humans. No controlled trial has tested this.
• Whether oral fisetin at any dose meaningfully affects hair follicles. The bioavailability ceiling makes this unlikely at typical supplement doses.
• Whether fisetin has any specific effect on melanocyte stem cells in the follicular bulge. Not characterised in any published study.
• Whether fisetin combined with minoxidil is additive, antagonistic, or neutral for hair growth. Untested.
• The optimal topical fisetin formulation for hair applications. Vehicles, concentrations, and application frequency all remain empirical.
Bottom line
Fisetin has one meaningful hair-growth paper — Sasaki 2020 — showing that topical fisetin activates TERT in follicular keratinocytes and promotes hair growth in mice (1). The finding is mechanistically interesting but translationally limited: no human trial has tested either oral or topical fisetin for hair outcomes, and the biology of grey hair (melanocyte stem cell dysfunction) is not addressed by any of the fisetin preclinical work. Reddit and longevity-forum reports of grey hair reversal are anecdotal and confounded. Evidence-based hair loss treatment (minoxidil, finasteride) remains the appropriate first-line therapy. Fisetin may reasonably be considered as an adjunct in an experimental hair regimen, but should not substitute for established treatment. For the full clinical context, see our complete clinician’s guide.
Frequently asked questions
Does fisetin actually regrow hair?
In mice, topical fisetin promotes hair growth (1). In humans, no clinical trial has tested this. Anecdotal reports exist but do not constitute clinical evidence.
Can fisetin reverse grey hair?
No controlled evidence supports this claim. Grey hair biology involves melanocyte stem cell dysfunction, which is not addressed by any of the fisetin preclinical work.
Should I use topical or oral fisetin for hair?
For hair-specific outcomes, topical is more mechanistically direct because it delivers meaningful concentrations to follicular tissue. Oral fisetin’s bioavailability ceiling limits follicular delivery.
Can I combine fisetin with minoxidil?
No documented interaction. The combination has not been studied. If you use both, apply them at different times of day to reduce vehicle interaction.
How long before I see hair changes with fisetin?
If fisetin produces any hair effect in humans, it would be visible over months, not weeks. Hair follicles cycle over 3–6 month periods. Any dramatic rapid change is more likely explained by other factors.
References
1. Sasaki M, Yasushi Y, Ohgomori T, et al. Fisetin promotes hair growth by augmenting TERT expression. Front Cell Dev Biol. 2020;8:566617. https://pmc.ncbi.nlm.nih.gov/articles/PMC7593534/
2. Rossi A, Cantisani C, Melis L, et al. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130-136. https://pubmed.ncbi.nlm.nih.gov/22409453/
3. Nishimura EK, Granter SR, Fisher DE. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science. 2005;307(5710):720-724. https://pubmed.ncbi.nlm.nih.gov/15618488/
4. Aoi N, Inoue K, Chikanishi T, Fujiki R, Yoshimura K. 1α,25-dihydroxyvitamin D3 modulates the hair-inductive capacity of dermal papilla cells: therapeutic potential for hair regeneration. Stem Cells Transl Med. 2012;1(8):615-626. https://pmc.ncbi.nlm.nih.gov/articles/PMC3659751/
5. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
6. Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin. J Nutr Sci. 2022;11:e74. https://doi.org/10.1017/jns.2022.72
7. Rosenberg AM, Rausser S, Ren J, et al. Quantitative mapping of human hair greying and reversal in relation to life stress. eLife. 2021;10:e67437. https://elifesciences.org/articles/67437
8. Sun Q, Lee W, Mohri Y, et al. A polycomb complex is required for maintenance of the pigmented state of hair follicle stem cells. Nature. 2023;616(7958):774-782. https://pubmed.ncbi.nlm.nih.gov/37076618/